Vicky joined Selcia in 2008 as a senior scientist and was promoted less than a year later to group leader where she managed and led key client discovery projects. She was promoted to Associate Director Discovery in 2013 and to Director, Discovery in 2015.
Vicky brings to Selcia significant big pharma experience having previously worked in senior scientific roles at GlaxoSmithKline (2005 – 2008) and Merck Sharp and Dohme (2002 – 2005). This was preceded by a two year placement in the USA as a Royal Society Fulbright Postdoctoral Fellow.
Her main areas of therapeutic interest and experience include anti-viral macrolides (Hepatitis C), anti-bacterials (MRSA), anti-inflammatory macrocyclic natural products, and kinase inhibitors and gamma-secretase modulators (both for Alzheimer’s disease). She is named on over 20 peer reviewed papers and patents.
Vicky has a BSc in chemistry from Imperial College and a PhD in organic chemistry from the University of Cambridge. She is a Fellow of the Royal Society of Chemistry and has served on the SCI’s Fine Chemicals Group Committee.